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Phenylalanine is an essential amino acid required for the synthesis of catecholamines including dopamine. Altered levels of
phenylalanine and its metabolites in blood and cerebrospinal ﬂuid have been reported in schizophrenia patients. This study
attempted to examine for the ﬁrst time whether phenylalanine kinetics is altered in schizophrenia using L-[1-
13C]phenylalanine
breath test (
13C-PBT).The subjects were 20 chronically medicated schizophrenia patients (DSM-IV) and the same number of age-
and sex-matched controls.
13C-phenylalanine (99 atom%
13C; 100mg) was administered orally and the breath
13CO2 /
12CO2 ratio
wasmonitoredfor120min.Thepossibleeffect ofantipsychoticmedication(risperidone (RPD)orhaloperidol(HPD)treatmentfor
21 days) on
13C-PBT was examined in rats. Body weight (BW), age and diagnostic status were signiﬁcant predictors of the area
under the curve of the time course of D
13CO2 (%) and the cumulative recovery rate (CRR) at 120min. A repeated measures
analysis of covariance controlled for age and BW revealed that the patterns of CRR change over time differed between the
patientsandcontrolsandthatD
13CO2waslowerinthepatientsthaninthecontrolsatallsamplingtimepointsduringthe120min
test, with an overall signiﬁcant difference between the two groups. Chronic administration of RPD or HPD had no signiﬁcant
effecton
13C-PBTindicesinrats.Ourresultssuggestthat
13C-PBTisanovellaboratorytestthatcandetectalteredphenylalanine
kinetics inchronicschizophreniapatients.Animalexperiments suggestthatthe observedchanges areunlikelytobeattributable
to antipsychotic medication.
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Introduction
L-Phenylalanine is an essential amino acid required for
catecholamine biosynthesis. Altered levels of phenylalanine
and its metabolites, including another precursor for dopamine
biosynthesis, the downstream amino acid tyrosine, could be
related to the dopamine hypothesis of schizophrenia.
1,2
Indeed, serum phenylalanine levels were found to be
signiﬁcantly higher,
3 and tyrosine levels lower
4 in drug-free
patientswith schizophreniathan inhealthycontrols. However,
Wei et al.
5 reported no signiﬁcant difference between serum
phenylalanine levels of drug-free schizophrenics and healthy
controls, although the ratio of tyrosine to phenylalanine was
signiﬁcantly lower in patients with early-onset disease than in
controls. The phenylalanine level in cerebrospinal ﬂuid was
signiﬁcantly higher in schizophrenia patients with or without
neuroleptics than in controls.
6 However, Potkin et al.
7 found
no signiﬁcant difference in plasma phenylalanine or tyrosine
levels between chronic schizophrenia patients with or without
neuroleptics and controls. Phenylethylamine, a metabolite of
phenylalaninethatis consideredanendogenousneuroamine,
was signiﬁcantly higher in plasma samples from medicated
patients with schizophrenia than in those from controls.
8,9
The enzyme phenylalanine hydroxylase (PAH) converts
phenylalanine to tyrosine using the cofactor tetrahydrobiop-
terin; this activity takes place in the liver and kidney.
10,11 The
PAH gene has been studied extensively in phenylketonuria
(PKU), an autosomal recessive genetic disorder character-
izedbymentalretardation,epilepsy,eczemaandotherclinical
manifestations.
12–14 Mutations in PAH are responsible for
over 98% of PKU cases and more than 500 causative
mutations have been reported (http://www.pahdb.mcgill.ca/).
13
The possible association between PKU and psychiatric
disorders was ﬁrst described in 1935 by Penrose,
15 who
stated that PKU mutation heterozygotes might be predis-
posed to mental disorders. In 1974, Kuznetsova studied 300
parents of PKU patients and suggested that PKU hetero-
zygotes may have increased susceptibility to late-onset
schizophrenia.
16,17 Although a recent molecular genetic study
focusing on two PKU-causing PAH mutations in 190 schizo-
phrenia patients and 336 controls reported a contradictory
negative result,
18 Richardson et al. found that a novel PAH
mutation, K274E, may possibly be associated with psychiatric
disorders in African-Americans.
19–21 Furthermore, the same
research group screened samples from 123 patients with
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www.nature.com/tppsychiatric disorders for PAH mutations and found decreased
phenylalanine kinetics in schizophrenia patients with the
K274E mutation compared with patients without the muta-
tion.
22 A meta-analysis including two eligible studies (164
cases and 51 controls) detected no signiﬁcant association
between PAH and schizophrenia.
23 However, two more
recent studies have suggested that PAH polymorphisms
confer susceptibility to schizophrenia
24 and modify features of
psychotic disorders.
25
The enzyme tyrosine hydroxylase (TH) uses tetrahydro-
biopterin to catalyze the conversion of tyrosine to L-3,4-
dihydroxyphenylalanine (L-DOPA), which is the rate-limiting
step in the syntheses of dopamine and noradrenaline.
10 One
of the mechanisms by which TH is regulated is feedback
inhibition by its end products, that is, dopamine and
noradrenaline.
26,27 TH is normally found in the adrenal glands
and central nervous system,
10,28 but a study of TH in
peripheral blood found overexpression of TH mRNA in
schizophrenia.
29 However, previous genetic studies
30,31 and
a meta-analysis
23 of reported studies has shown no positive
evidence for an association between genetic polymorphisms
in TH and schizophrenia.
13C-labeled substrates have been applied for various rapid,
noninvasive breath tests in medicine.
32 The L-[1-
13C]pheny-
lalanine breath test (
13C-PBT) has been used to measure the
in vivo activity of the PAH enzyme in PKU.
33,34 Yamashita
et al.
35 ﬁrst described the use of the
13C-PBT in patients with
psychiatric disorders, administering 100mg per body of
L-[1-
13C]phenylalanine (
13C-phenylalanine) to 4 patients with
depression and 11 healthy control subjects and describing
changes of the pattern of phenylalanine kinetics in depression
patients. Although phenylalanine, tyrosine and the enzymes
involved in their metabolisms have been thoroughly studied in
the brain and periphery, as outlined above, we could ﬁnd no
previous reports on the administration of
13C-PBT, which
provides a real-time assessment of the whole-body kinetics
and metabolism of phenylalanine, in patients with schizo-
phrenia or mood disorders.
The aim of the present study was to examine whether
phenylalanine kinetics as assessed by
13C-PBT are altered in
schizophrenia patients. Given that reduced PAH activity may
be related to schizophrenia susceptibility, we hypothesized
that phenylalanine metabolism is suppressed in schizophre-
nia patients. We also performed experiments in rats to
elucidate the possible effects of typical or atypical antipsy-
chotic medication on phenylalanine kinetics.
Materials and methods
Participants. The subjects were 20 schizophrenia patients
and the same number of healthy age- and sex-matched
controls. The patients were recruited from the National
Center of Neurology and Psychiatry (NCNP) Hospital and
associated psychiatric hospitals (Henmi Hospital and
Yamada Psychiatric Hospital). These hospitals are located
in the same geographical area in the western part of
metropolitan Tokyo. The schizophrenia patients were
diagnosed according to the Diagnostic and Statistical
Manual of Mental Disorders, 4th edition (DSM- IV) criteria
36
and careful examination of medical records by the consensus
of at least two experienced psychiatrists. Age- and sex-
matched healthy controls were recruited through
advertisements in free local information magazines and by
announcements on our website. All healthy control subjects
were screened by psychiatrists using the Japanese version
of the Mini-International Neuropsychiatric Interview
(MINI)
37,38 to conﬁrm no past or current history of major
psychiatric illness. Participants were excluded if they were
pregnant or lactating, reported psychoactive drug use or
alcohol abuse within the previous 6 months, or had a history
of severe head injury, an endocrine disease, a respiratory
disease, or a serious physical disorder, especially any type of
disease of the kidneys or liver, where phenylalanine is mainly
metabolized. Participants underwent blood testing of aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
cholinesterase (ChE), blood urea nitrogen and creatinine
levels to rule out kidney or liver dysfunction. Data on total
protein, albumin, total bilirubin and platelet counts were also
collected from the patients’ medical records to check liver
function, although one patient was missing such data.
Individuals who showed any blood test abnormalities were
not enrolled in the study. All participants were biologically
unrelated Japanese who resided in the western part of
Tokyo. The present study was approved by the ethics
committee of the NCNP. Signed informed consent was
obtained from each subject after a detailed description of the
study aim and protocol.
Principle of the
13C-PBT. The kinetic values for L-[1-
13C]
phenylalanine represent those for unlabeled phenylalanine.
39
Orally administered phenylalanine is absorbed at the brush
border membrane of the proximal small intestine. Approxi-
mately three-fourths of absorbed dietary phenylalanine is
irreversibly converted to tyrosine by PAH in the liver and
kidney.
10,11,24 The most quantitatively important route of
tyrosine metabolism is degradation to p-hydroxyphenyl-
pyruvic acid and then homogentisic acid by transamination
and subsequent decarboxylation, respectively.
40 The other
two major pathways of phenylalanine metabolism are the
conversion of tyrosine into tyramine by aromatic amino acid
decarboxylase and the conversion of L-DOPA into dopamine
by aromatic amino acid decarboxylase in the adrenal glands
and central nervous system (Figure 1).
10,28,41 The
13CO2
derived from administered
13C-phenylalanine can be
produced not only by the three main pathways but also by
other, minor ones: the conversion of phenylalanine to
phenylethylamine and melanin synthesis from tyrosine. The
13CO2 /
12CO2 ratio measured in the
13C-PBT is expected to
reﬂect the total
13CO2 produced in vivo from administered
13C-phenylalanine through all of the mechanisms described
above, although the three main pathways are the major
contributors to
13CO2 production.
The D
13CO2 (%) at each sampling point was calculated
from the infrared (IR) absorption intensities of
13CO2
(2280±10cm
 1) and
12CO2 (2380±10cm
 1) by IR spectro-
metry (Equation (A) in Supplementary Table S1).
33,42 Then,
data were obtained on the maximal D
13CO2 (Cmax; %) and
time to reach the maximal D
13CO2 (Tmax; min). The amount of
13C-phenylalanine metabolized and exhaled as
13CO2 within
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Translational Psychiatry120min was expressed as the cumulative recovery rate
(CRR; %) and area under the D
13CO2-time curve (AUC;
%*min). The CRR was deﬁnedas the ratio of the total amount
of exhaled
13CO2 to the administered dose of
13C-phenyl-
alanine (Equation (B) to (E) in Supplementary Table S1).
43
13C-PBT procedures. The method of
13C-PBT was
performed as previously described.
44 Participants were
instructed to fast beginning at 0000 hours, drink water (but
no juice, alcohol or other beverages) liberally, and refrain
from smoking for at least 3h before the breath test. Fasting
blood samples were drawn before the start of the breath test.
The blood samples were allowed to stand at room
temperature for at least 30min and separated by
centrifugation at 3000r.p.m. for 10min. Supernatants were
stored as serum at  201C until biochemical analysis for
AST, ALT, ChE, blood urea nitrogen and creatinine levels by
SRL Corporation (Tokyo, Japan). The baseline breath
samples were collected twice into special breath-sampling
bags (retention volume: 1300ml each; Otsuka Electronics,
Osaka, Japan). The subjects then drank aqueous solutions
of
13C-phenylalanine (99 atom%
13C; Cambridge Isotope
Laboratories, Cambridge, UK), 100mg per subject in 100ml
of water, at 1000h. Breath samples were collected into
special breath-sampling bags (retention volume: 250ml
each; Otsuka Electronics) 10, 15, 20, 30, 45, 60, 90 and
120min after ingestion of the
13C-phenylalanine solution. All
breath samples were collected after 10sec of breath holding,
which allows mixing of the gas in both the trachea and
pulmonary alveoli to decrease the effects of respiratory dead
space. Throughout the
13C-PBT, participants were instructed
to remain quietly in a resting position. The
13CO2 /
12CO2 ratio
of the special breath-sampling bags was analyzed by IR
spectrometry (UBiT-IR300 and UBiT-AS10, Otsuka
Pharmaceutical, Tokyo, Japan) within 3 days of collection
of each breath sample.
Clinical status and antipsychotic medication. The
participants with schizophrenia were considered relatively
stable on antipsychotic drugs. Current clinical symptoms in
schizophrenic subjects were assessed using the positive and
negative symptom scale (PANSS) and its Positive, Negative
and General Psychopathology subscales.
45 PANSS scoring
was performed by a single experienced psychiatrist. Doses
of antipsychotics and depot antipsychotics were converted to
chlorpromazine equivalents (CPZeq) according to published
guidelines.
46,47
Animals. Male Wistar rats weighing 300–400g at postnatal
day 42 were obtained from Charles River Laboratories
(Yokohama, Japan) for analysis of the inﬂuence of antipsycho-
tics on the
13C-PBT results. Rats were housed under standard
lighting conditions on a 12:12-h light:dark cycle and provided
food and water ad libitum. All experimental procedures were
approved by the ethics review committee for animal experi-
mentation at the National Institute of Neuroscience, Japan
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Figure 1 Schematic diagram illustrating main routes for L-[1-
13C]phenylalanine (
13C-phenylalanine) metabolism. The conversion of phenylalanine to tyrosine is observed
in the liver and kidney and is the main step of the metabolism of phenylalanine. The most quantitatively major three pathways for tyrosine metabolism is the degradation
forming p-hydroxyphenylpyruvic acid and homogentisic acid, the conversion of tyrosine into tyramine and the conversion of L-DOPA into dopamine via tyrosine. In all of the
main three routes,
13CO2 was exhaled. The
13CO2 /
12CO2 ratio measured in the
13C-phenylalanine breath test is expected to reﬂect the total
13CO2 produced in vivo from
administered
13C-phenylalanine through these reaction routes. Minor pathways and pathways without release of
13CO2 were omitted. Circles upon the carbon mark
13C-
labeled carbon. Striped arrows indicate the multiple consecutive reactions. PAH, phenylalanine hydroxylase; TH, tyrosine hydroxylase; AADC, aromatic amino acid
decarboxylase; TAT, tyrosine transaminase; HPPD, 4-hydroxyphenylpyruvic acid dioxygenase; DBH, dopamine b-hydroxylase; L-DOPA, L-3,4-dihydroxyphenylalanine;
PNMT, phenylethanolamine N-methyltransferase; TYR, tyrosinase.
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care and use of animals.
13C-PBT in rats. The animal studies were performed during
P56 to 80. Rats were randomly assigned to receive vehicle,
risperidone (RPD), or haloperidol (HPD) for 21 days (N¼15
for each group). RPD oral solution (1.0mgml
–1; Janssen
Pharmaceuticals, Antwerp, Belgium) was administered in the
rats’ drinking water. HPD (Sigma-Aldrich Japan, Tokyo,
Japan) was dissolved in 0.1 M citric acid and administered
diluted 1:100 in the rats’ drinking water. The body weight
(BW) and water or solution consumption of each rat were
checked ﬁve times a week to adjust the concentrations of the
solutions so that the rats received RPD or HPD at doses of
2.5 or 2.0mgkg
–1 per day, respectively, for 21 days. This
duration of drug treatment was chosen based on prior reports
that described the pharmacological effects of RPD and HPD
in rats.
48,49 On the 21st day of drug administration, we
checked the blood HPD concentrations of six rats randomly
chosen from the 15 rats of the HPD group. The mean level of
the blood HPD concentration was 6.8±4.3ngml
–1, which is
enough to induce pharmacological effects in rats.
50 After 21
days of treatment, rats were fasted for over 15h in mesh-
ﬂoor cages (to prevent coprophagy) with 60ml water. During
the dark phase, fasted rats were injected intraperitoneally
with saline solution containing 0.1%
13C-phenylalanine
(10mlkg
–1 BW) and placed individually in an animal
chamber (PC-250K, 9000ml, Sanplatec, Osaka, Japan)
connected to an auto-breath collect device (Auto-breath
collector, Otsuka Electronics), with a pump (Vacuum pump
VP0125, Nitto Kohki, Tokyo, Japan) controlled by a pro-
grammed timer (PRO-io2, Digital Electronics, Osaka, Japan)
for gas exchange in the chamber (Supplementary Figure S1).
The air of the chamber was ﬁltered (Millex FA, Millipore, MA,
USA) and collected automatically into the special breath-
sampling bags by the auto-breath sampling system as breath
samples 10, 20, 30, 45, 60, 90 and 120min after the injection
of
13C-phenylalanine. To avoid excessive accumulation
of expired CO2 gas, the chamber air was continuously
exchanged by the pump with programmed timer through a
hole (10mm) on the chamber ceiling throughout the 120min
test except for the 8 and 12min allowed for breath
accumulation before the 10, 20 and 30min and 45, 60, 90
and 120min sampling points, respectively (Supplementary
Figure S2).
Statistical analysis. The Statistical Package for the Social
Sciences (SPSS) version 11.0 (SPSS Japan, Tokyo, Japan)
was used to conduct all statistical tests, except for 95%
conﬁdence interval (CI), which was analyzed using the R
software (http://www.r-project.org). General descriptions of
continuous variables were expressed as mean±s.d.
Differences in blood test values between the patients and
controls were examined by using the t-test. The correlation
between each index of
13C-PBT (AUC, CRR0–120, and Cmax)
and each value of liver blood tests was examined using the
Pearson’s correlation analysis. The normality and the
homoscedasticity of the dependent variables were checked,
and stepwise multiple regression analyses were employed to
examine the effect of diagnostic status (patients/controls) on
indices of
13C-PBT (AUC, CRR0 120, and Cmax), controlling
for gender, age and BW. A 2 8 (group sampling point)
repeated measures analysis of covariance (ANCOVA) was
conducted to examine group differences in D
13CO2 or CRR
over time, controlling for age. Greenhouse–Geisser
corrections were applied for lack of sphericity. The Cmax,
AUC and CRR0–120 were compared between the patients
and controls using the t-test and ANCOVA, controlling for
age and BW and for age, BW and ALT. Tmax was the value of
a discrete variable and was compared between the two
groups using the Mann–Whitney test. In patients, the
correlation between each index of
13C-PBT (AUC, CRR0–120,
and Cmax) and CPZeq and PANSS total score was examined
using Pearson’s correlation analysis. A stepwise multiple
regression was employed to assess independent predictors
of AUC, CRR0–120 and Cmax, using gender, age, BW, CPZeq
and PANSS total score as candidate predictors. For analysis
of animal experiment results, a 3 7 (Group sampling
point) repeated measures analysis of variance (ANOVA) was
conducted to examine differences in D
13CO2 over time
between experimental groups. The Cmax and AUC were
compared between experimental groups using one-way
ANOVA and the Tmax by the Kruskal–Wallis test. The mean
difference and median difference of the Cmax and AUC, and
Tmax, respectively, among experimental groups and its 95%
CI were calculated. Two-tailed p values o0.05 were
considered signiﬁcant.
Results
Demographic and clinical characteristics of patients and
controls. The demographic and clinical characteristics of
the patients and controls are shown in Table 1. Laboratory
assessments of the liver and kidneys of all subjects fell within
the normal ranges, although ALT was slightly, but
signiﬁcantly increased in the patients compared with that in
the controls (t(30.1)¼2.40, P¼0.023). The duration of
illness of the schizophrenia patients was 19.1±13.3 years.
The majority (85%) of the schizophrenia patients were
chronic inpatients, and the mean length of hospitalization
was 2.7±4.3 years at the time of the
13C-PBT; this duration
would not be considered unusually long in Japan, where
long-term hospitalization due to disability in daily living is
common, so that psychiatric hospitalization does not
necessarily mean that the patient is in the acute phase of
illness. The drug regimen of 17 of 20 of the schizophrenic
participants had not been changed over the previous 3
months. Relatively large doses of antipsychotics were
prescribed. These data demonstrate that the majority of the
schizophrenic participants were in the chronic phase.
Predictors of indices of
13C-PBT. The results of the
stepwise regression analyses are shown in Table 2. BW
(b¼ 0.458, P¼0.002) and diagnostic status (b¼ 0.281,
P¼0.047) were signiﬁcant predictors of Cmax.B W
(b¼ 0.503, Po0.001), age (b¼0.295, P¼0.023) and
diagnostic status (b¼ 0.261, P¼0.044) were signiﬁcant
predictors of AUC and entered into the ﬁnal regression
13C-phenylalanine breath test in schizophrenia
T Teraishi et al
4
Translational Psychiatrymodel. BW (b¼ 0.318, P¼0.025), age (b¼0.346,
P¼0.015) and diagnostic status (b¼ 0.304, P¼0.032)
were signiﬁcant predictors of CRR0–120. Gender was not a
signiﬁcant predictor of any of these indices of
13C-PBT (data
not shown).
Decreased Cmax, AUC and CRR in schizophrenia. The
results of the
13C-PBT are shown in Figure 2 as the time
course of mean values of D
13CO2 (Figure 2a) and CRR
(Figure 2b) in the patients and controls. The repeated
measures ANCOVA controlling for age and BW indicated a
signiﬁcant difference in D
13CO2 over time between the two
groups (F(1, 36)¼4.57, P¼0.039). The repeated measures
ANCOVA with Greenhouse–Geisser adjustment revealed no
signiﬁcant interaction between the diagnostic status and
sampling point (F(1.81, 65.04)¼2.55, P¼0.091). The
repeated measures ANCOVA controlling for age and BW
indicated a signiﬁcant difference in CRR over time between
the patients and controls (F(1, 36)¼4.87, P¼0.034). The
repeated measures ANCOVA with Greenhouse–Geisser
adjustment revealed a signiﬁcant interaction between the
diagnostic status and sampling point (F(1.09, 39.26)¼4.73,
P¼0.033, Table 3), implying different patterns of change in
CRR over time in the patients and controls. D
13CO2 values
were lower in the patients than in the controls at all sampling
points during the 120min test, with an overall signiﬁcant
difference between the two groups.
The Cmax was signiﬁcantly lower in the patients than in the
controls (t(38)¼2.07, P¼0.046) and remained signiﬁcantly
different in the ANCOVA controlling for age and BW (F(1,
36)¼4.53, P¼0.040). The Tmax did not differ signiﬁcantly
between the two groups (U¼134.5, P¼0.076, Mann–
Whitney test). The AUC tended to be smaller in the patients
than in the controls (t(38)¼1.92, P¼0.063); this trend
Table 2 Stepwise multiple regression for L-[1-
13C]phenylalanine breath test indices as dependent variables
Dependant variable Predictor variable
a b Adjusted r
2 P
Cmax Body weight (kg)  0.458 0.273 0.002
Diagnostic status
b  0.281 0.047
AUC Body weight (kg)  0.503 0.396 o0.001
Age (year) 0.295 0.023
Diagnostic status  0.261 0.044
CRR0 120 Body weight (kg)  0.318 0.282 0.025
Age (year) 0.346 0.015
Diagnostic status  0.304 0.032
Abbreviations: AUC, area under the D
13CO2-time curve; Cmax, the maximal D
13CO2 (%); CRR0 120, the cumulative recovery rate during the 120min test.
aPossible predictor variables included diagnostic status, sex, age and body weight.
bDiagnostic status was measured on a nominal scale: 1¼healthy control;
2¼schizophrenia.
Table 1 Demographic and clinical variables of schizophrenia patients and healthy controls
Patients Controls t-test (P)
Gender (male/female) 10/10 10/10
Age (year) 47.9±13.4 47.6±14.6 0.937
Body weight (kg) 63.2±12.0 61.5±9.8 0.625
Body mass index (kg/m
2) 24.1±4.0 23.0±2.6 0.311
Age of onset (year) 28.9±10.8
Duration of illness (year) 19.1±13.3
Number of inpatients (%) 17 (85.0)
Psychopathology score (PANSS)
Total 61.4±13.3
Positive scale 11.3±3.7
Negative scale 19.0±7.3
General psychopathology scale 31.1±7.0
CPZeq (mg per day) 844.0±639.6
AST (Ul
–1, reference value:10–40) 19.1±6.1 18.7±4.5 0.792
ALT (Ul
–1, reference value:5–40) 18.9±10.5 12.4±6.0 0.023
Cholinesterase (Ul
–1, reference value: m 242–495; f 200–459) 300.9±90.3 327.7±57.3 0.269
BUN (mgdl
–1, reference value: 8.0–22.0) 10.0±2.9 12.6±3.7 0.018
Cr (mgdl
–1, reference value: m, 0.61–1.04; f, 0.47–0.79) 0.68±0.15 0.68±0.13 0.938
Total protein (gdl
–1, reference value: 6.7–8.3) 7.0±0.5
Albumin (gdl
–1, reference value: 3.8–5.3) 4.3±0.5
Total bilirubin (mgdl
–1, reference value: 0.2–1.2) 0.5±0.2
Platelet counts ( 10
4 per ml, reference value: 14–35) 22.1±5.5
Abbreviations: BUN, blood urea nitrogen; CPZeq, total antipsychotic dose in chlorpromazine equivalents; Cr, creatinine; f, female; m, male; PANSS, positive and
negative symptom scale.
One patient was missing the total protein, albumin, total bilirubin and platelet counts data.
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(F(1,36)¼4.37,P¼0.044)andintheANCOVAcontrollingfor
age, BW and ALT (F(1, 35)¼6.25, P¼0.017). The CRR0–120
was signiﬁcantly smaller in the patients than in the controls
(t(38)¼2.12, P¼0.041) and remained signiﬁcant in the
ANCOVA controlling for age and BW (F(1, 36)¼4.99,
P¼0.032). These results are presented in Supplementary
Table S2.
Clinical variables and
13C-PBT in the patients. There was
no signiﬁcant correlation between each index of
13C-PBT and
each value of liver blood tests in subjects (Supplementary
Table S3).
We analyzed whether the symptom severity of schizo-
phrenia and antipsychotic medication affected any patient
indicesof
13C-PBT.NoneoftheCmax,AUCorCRR0 120inthe
patients correlated signiﬁcantly with the PANSS total score or
CPZeq (data not shown). Further, stepwise multiple regres-
sion analysis found only age to be a signiﬁcant predictor of
Cmax, AUC and CRR0 120, whereas no other variables, such
as sex, BW, PANSS total score or CPZeq, ever entered into
these regression models (Supplementary Table S4).
Animal experiments. We investigated whether typical or
atypical antipsychotic medication affected any index of
13C-
PBT in rats. The results of the
13C-PBT are shown in
Figure 2c as the time course of the mean values of D
13CO2 in
the vehicle, RPD and HPD groups. A repeated measures
ANOVA demonstrated no statistically signiﬁcant main
effect of group on D
13CO2 (F(2, 42)¼0.84, P¼0.439,
Supplementary Table S5). The repeated measures ANOVA
with Greenhouse–Geisser adjustment revealed no signiﬁcant
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Figure 2 (a) Time courses of
13CO2 excretion by schizophrenia patients and
healthy controls during L-[1-
13C]phenylalanine breath test. (b) Time courses of
cumulative recovery rate (CRR; %) in schizophrenia patients and healthy controls
during L-[1-
13C]phenylalanine breath test. (c) Time courses of
13CO2 excretion by
rats of vehicle group, risperidone (RPD) group and haloperidol (HPD) group during
L-[1-
13C]phenylalanine breath test. Values are expressed as mean. SZ,
schizophrenic group; CON, control group; Time, time after ingesting the solution
of L-[1-
13C]phenylalanine (99 atom%
13C; 100mg).
Table 3 Repeated measures analysis of covariance in schizophrenia patients
and healthy controls for change in D
13CO2 and CRR during the 120min
L-[1-
13C]phenylalanine breath test
Parameter Patients
(n¼20)
Controls
(n¼20)
Repeated
measures
ANCOVA
a
Mean±s.d. Mean±s.d. FP
D
13CO2
D
13CO2 at 10min (%) 6.8±6.8 10.2±7.3
D
13CO2 at 15min (%) 9.6±7.9 15.5±8.6
D
13CO2 at 20min (%) 11.5±7.9 15.9±6.7
D
13CO2 at 30min (%) 10.1±5.6 13.1±4.6
D
13CO2 at 45min (%) 7.4±3.4 8.7±2.5
D
13CO2 at 60min (%) 5.7±2.5 6.9±2.0
D
13CO2 at 90min (%) 3.8±1.6 4.6±1.6
D
13CO2 at 120min (%) 2.7±1.3 3.2±1.1
Interaction
b 2.55 0.091
Between group 4.57 0.039
CRR
CRR at 10min (%) 0.5±0.5 0.8±0.5
CRR at 15min (%) 1.2±1.1 1.8±1.1
CRR at 20min (%) 2.0±1.6 3.0±1.5
CRR at 30min (%) 3.7±2.5 5.2±2.1
CRR at 45min (%) 5.8±3.3 7.8±2.6
CRR at 60min (%) 7.3±3.8 9.6±2.9
CRR at 90min (%) 9.5±4.6 12.3±3.5
CRR at 120min (%) 11.0±5.1 14.1±4.0
Interaction
b 4.73 0.033
Between group 4.87 0.034
Abbreviations:ANCOVA,analysisofcovariance;CRR,thecumulativerecovery
rate.
aRepeated measures analysis of covariance with age and body weight as
covariates.
bInteraction between diagnostic status and sampling point.
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mean Cmax and AUC values were lower in the vehicle group
than in the RPD or HPD group, one-way ANOVA revealed
no signiﬁcant difference in Cmax or AUC between the
experimental groups (Supplementary Table S6). Median
Tmax did not differ among the three groups. Mean
differences of Cmax among groups were as follows: vehicle
vs RPD, 0.7% (95% CI, 4.0–2.6%); vehicle vs HPD, 1.0%
(95% CI, 3.3–1.3%). Mean differences of AUC among
groups were as follows: vehicle vs RPD, 84.1% (95% CI,
395.0–226.9%); vehicle vs HPD, 107.8% (95% CI, 306.4–
90.8%). Median differences of Tmax among groups were as
follows: vehicle vs RPD, 0min (95% CI, 0–25min); vehicle vs
HPD, 0min (95% CI, 0–15min).
Discussion
We found signiﬁcant differences in
13C-PBT indices between
the schizophrenia patients and healthy controls. Diagnostic
status (schizophrenia/control) was found to be a signiﬁcant
predictor of the
13C-PBT indices Cmax, AUC and CRR0 120.A
repeated measures ANCOVA controlling for age and BW
revealed different patterns of change in CRR over time in the
two groups; D
13CO2 values (%) were lower in the schizo-
phrenia patients than in the controls at all sampling points
during the 120min test, with an overall signiﬁcant difference
between the two groups. In the patient group, none of Cmax,
AUC or CRR0 120 was signiﬁcantly correlated with symptom
severity or dose of antipsychotic medication, and the animal
experiments demonstrated that chronic administration
of RPD or HPD had no signiﬁcant effect on any index of
13C-PBT, indicating that the observed differences in the
13C-
PBT indices were unlikely to be attributable to antipsychotic
medication. To our knowledge, this is the ﬁrst report
that utilizes the
13C-PBT to demonstrate decreased phenyla-
lanine kinetics in schizophrenia. Our results agree with
previous reports of abnormal phenylalanine metabolism in
schizophrenia.
4,8,51
The
13C-PBT has been shown to be useful for assessing
hepatic function and PAH activity, as phenylalanine is
metabolized by PAH predominantly in the liver as well as in
the kidney.
11,52,53 Considering this effect, we screened the
subjects and excluded those subjects with abnormal hepatic
or renal parameters (that is, AST, ALT, ChE, blood urea
nitrogenandcreatininelevelsofthe patientsandcontrols,and
total protein, albumin, total bilirubin and platelet counts of the
patients). ChE, in particular, was reported to be signiﬁcantly
correlated positively with the
13C-PBT results.
52 We con-
ﬁrmed that there was no statistically signiﬁcant difference in
ChE between the patients and controls (Table 1). ALT was
slightly, but signiﬁcantly, increased in the patients compared
with that in the controls (Table 1). However, the ALT levels in
the patients were all within the normal range. Additionally, a
previous study reported that ALT level did not correlate with
13C-PBT results.
52 In our data, Pearson’s correlation coefﬁ-
cientsbetweenindicesof
13C-PBT(AUC,CRR0–120andCmax)
and ALT in the patients were all close to 0 (r¼0.01, r¼0.09
and r¼0.04, respectively; Supplementary Table S3). Further-
more, when ANCOVA was conducted to compare AUC
between the patients and controls, controlling for ALT as well
as age and BW, the obtained P values for AUC decreased
from 0.044 (ANCOVA controlling for age and BW, Supple-
mentary Table S2) to 0.017 rather than increased. All these
data ensure that increased ALT within the normal range was
unrelated to the decreased
13C-PBT results observed in our
patients. Besides ALT, none of indices of
13C-PBT correlated
signiﬁcantly with the liver blood test values in subjects
(Supplementary Table S3). Therefore, the observed differ-
enceinthe
13C-PBTindicesbetweenthepatientsandcontrols
is unlikely to be attributable to impaired liver or kidney function
in the patients.
In PKU, which shows decreased
13C-PBT indices,
33,34
excess phenylalanine occurs in the brain leading to compe-
titive inhibition of the transport of other large neutral amino
acids at the blood–brain barrier. The cerebral imbalance of
phenylalanine and these amino acids has been thought to
causedecreasedsynthesisofmyelinandneurotransmittersin
the brain, which could result in mental retardation and other
brain dysfunctions, although the mechanism remains to be
fully elucidated.
54 The postulated pathogenesis of brain
dysfunction in PKU could overlap that of schizophrenia. Our
results suggest that treatment of phenylalanine imbalance
may have a therapeutic potential in schizophrenia.
The D
13CO2 measured in the
13C-PBT involves the amount
of change in
13CO2 produced by the conversion of L-DOPA
into dopamine, although this reaction is a quantitatively minor
pathway for the synthesis of
13CO2 and occurs in both the
brain and the periphery. The decreased
13C-PBT indices in
schizophrenia may have resulted in part from decreased
catecholamine synthesis. This could in turn lead to compen-
satorydopaminereceptorsupersensitivity,whichisinlinewith
the dopamine hypothesis of schizophrenia.
51
The parameters measured by the
13C-PBT are inﬂuenced
not only by the metabolic pathways mentioned above but also
by other complicated physiologic and cell biological factors
in vivo, including fasting period, gastric emptying rate, rate of
digestive absorption, rate of uptake by the liver or kidneys,
transport of phenylalanine and its metabolites across the
plasma membrane.
33 In the current study, Tmax was not
signiﬁcantly different between the patients and controls and
the fasting period was consistent (that is, at least 10h),
suggesting that the indices were only marginally inﬂuenced by
the rate of digestive absorption or the dietary composition.
44
This study has several limitations. First, the sample size
was small. Second, our subjects were all medicated, although
both human and animal data showed no signiﬁcant effect of
antipsychotic medication on the
13C-PBT indices. Replication
studies with a larger sample size, preferably including drug-
freepatients,arewarranted.Third,themajorityofthesubjects
were inpatients, implying that severe forms of schizophrenia
were overrepresented in our sample.
In conclusion, the
13C-PBT provided evidence of altered
whole-body kinetics of phenylalanine in neuroleptic-treated
chronic schizophrenia. The
13C-PBT may detect a subgroup
of schizophrenia patients whose phenylalanine kinetics is
altered. Breath tests utilizing stable isotopes such as
13C-PBT
are simple, noninvasive, economical and repeatable labora-
tory tools that can be applied to a variety of metabolic
abnormalities and may drive innovation in future psychiatric
practice.
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